CRISPR Therapy CTX310 Reduces LDL Cholesterol by Over 50 Percent for One Year in Trial

A Phase 1a clinical trial has demonstrated that a single intravenous infusion of an investigational CRISPR-Cas9 therapy, known as CTX310, can significantly and sustainably lower cholesterol levels for at least one year. The study involved 15 patients diagnosed with various lipid disorders who were treated with the therapy to target the ANGPTL3 protein. Results presented at the European Society of Cardiology Congress 2026 and published in the New England Journal of Medicine revealed that patients receiving the highest dose of 0.8 mg/kg experienced a mean 52.5% drop in LDL cholesterol. This achievement represents a major step forward in the development of one-time genetic treatments for chronic cardiovascular conditions that typically require daily management.

The technical mechanism behind CTX310 involves the use of CRISPR-Cas9 gene-editing technology to precisely target and modify the ANGPTL3 gene within the body. This specific gene is responsible for producing a protein that inhibits enzymes involved in the clearance of triglycerides and cholesterol from the bloodstream. By reducing the presence of ANGPTL3, the therapy allows the body to more effectively process and remove these lipids naturally. In the trial, the ANGPTL3 protein itself was reduced by a mean of 78.6%, with some patients seeing reductions as high as 89%. This durable genetic modification offers a potential alternative to lifelong daily medications or frequent injections for managing high cholesterol and related metabolic issues.

The clinical trial was a collaborative effort led by Dr. Luke Laffin, a cardiologist at the Cleveland Clinic, and conducted across multiple research sites in Australia and New Zealand. During the implementation phase, 15 participants were monitored closely to assess both the efficacy and the safety of the intravenous infusion over an extended period. The researchers focused on the long-term stability of the gene editing, checking lipid levels at regular intervals over the course of twelve months to ensure the effects did not diminish. Importantly, the study reported that there were no serious treatment-related adverse events among the participants. This safety profile is a critical factor as the developer, CRISPR Therapeutics, prepares to advance the therapy into Phase 1b trials.

Beyond the immediate health benefits for the trial participants, the success of CTX310 carries broader implications for public health and the management of refractory dyslipidemias. High levels of LDL cholesterol and triglycerides are primary risk factors for heart disease and stroke, which remain leading causes of mortality worldwide. A one-time treatment that provides year-long or potentially permanent lipid management could significantly reduce the burden on global healthcare systems. It also addresses the challenge of patient adherence, as many individuals struggle to maintain the strict medication regimens required for conventional cholesterol management. The sustained 47.8% drop in triglycerides further highlights the therapy's comprehensive impact on improving lipid profiles in high-risk patients.

Looking toward the future, the successful completion of this Phase 1a trial sets the stage for larger, more diverse clinical studies to confirm these findings. CRISPR Therapeutics is currently moving forward with Phase 1b trials to refine dosing and confirm the long-term durability of the treatment across a wider patient population. If subsequent phases continue to show safety and efficacy, CTX310 could become a cornerstone in the treatment of genetic lipid disorders. The global significance of this research lies in its proof-of-concept for using CRISPR-Cas9 to treat common chronic diseases rather than just rare genetic conditions. This milestone suggests a future where cardiovascular health can be managed through precise and durable genetic interventions.